ABPI response to COVID antivirals announcement

The government has made a deal to secure 2 new antiviral COVID-19 treatments for this winter, which could see thousands of patients benefit.

Vaccines have already done so much to help break the link between infections and hospitalisations. Antivirals are another line of defence for the most clinically vulnerable and patients who are seriously ill with COVID-19. Richard Torbett, Chief Executive of the ABPI

Should the treatments be approved by the MHRA, they are expected to be given to those most at risk from the virus, helping reduce the severity of symptoms and ease pressure on the NHS over winter.

In response Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry, said:

“Vaccines have already done so much to help break the link between infections and hospitalisations. Antivirals are another line of defence for the most clinically vulnerable and patients who are seriously ill with COVID-19. This is good news, and another example of the pharmaceutical industry and government working together to make sure we have as many effective tools as possible to tackle this pandemic.”

 

TAGS
  • COVID 19

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.